Identification of Potential Regulatory Genes Associated with Chondrosarcoma using Integrated Bioinformatic Analysis
Abstract
Identifying the novel critical regulatory genes in the molecular processes driving chondrosarcoma (CS) growth is essential for establishing targeted therapeutic approaches. Objective: This study aims to investigate the core regulatory genes implicated in the molecular mechanisms of CS progression. Method: We conducted a dataset search from the Gene Expression Omnibus (GEO) database using “chondrosarcoma” as the keyword. DAVID database was utilised to obtain the Gene Ontology (GO) and pathways enrichment of DEGs. Interaction between the proteins network was constructed using the STRING database and visualised by Cytoscape (3.10.0) software. Subsequently, the essential genes were identified as the intersected genes from cytoHubb and MCODE plugin. Furthermore, we analysed these genes based on their expression and survival using the UALCAN database. Additionally, the cBioPortal database and Tumor Immune Estimation Resource (TIMER) were utilised to obtain the genetic alteration and immune cell infiltration associated with the hub genes. Moreover, the NetworkAnalyst database was deployed to construct the interactions between microRNAs (miRNAs) and the hub genes. Results: 114 common DEGs were found between two datasets (GSE30844 and GSE48418). These genes are predominantly associated with Focal Adhesion. Seven hub genes were identified which include CCND1, CDK6, CAV1, MLC1, SQSTM1, GAPDH, and FOXO1. The validation analysis revealed a diagnostic value amidst the hub genes, particularly CDK6 and FOXO1 genes associated with unfavorable outcome in sarcoma patients. The miRNAs analysis demonstrated that miR-15a-5p has a potential binding with CDK6 and FOXO1. Conclusions: This study revealed seven core genes and indicated a putative regulatory molecule associated with CS progression. Taken together, this study's findings suggest that the CDK6, FOXO1, and miR-15a-5p have a potential role in regulating CS progression.
References
Amer, K. M., Munn, M., Congiusta, D., Abraham, J. A., & Basu Mallick, A. (2020). Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis. Journal of Orthopaedic Research, 38(2), 311–319. https://doi.org/10.1002/jor.24463
Apley, G. (2019). Apley’s System of Orthopaedics and Fractures (10th ed.). Hodder Arnold.
Bader, G. D., & Hogue, C. W. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4(2), 1–25.
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., Chiang, D. Y., Reva, B., Mermel, C. H., Getz, G., Antipin, Y., Beroukhim, R., Major, J. E., Hatton, C., Nicoletti, R., … Singer, S. (2010). Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 42(8), 715–721. https://doi.org/10.1038/ng.619
Bartel, D. P. (2009). MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136(2), 215–233. https://doi.org/10.1016/j.cell.2009.01.002
Casimiro, M. C., Crosariol, M., Loro, E., Li, Z., & Pestell, R. G. (2012). Cyclins and Cell Cycle Control in Cancer and Disease. Genes & Cancer, 3(11–12), 649–657. https://doi.org/10.1177/1947601913479022
Chandrashekar, D. S., Karthikeyan, S. K., Korla, P. K., Patel, H., Shovon, A. R., Athar, M., Netto, G. J., Qin, Z. S., Kumar, S., Manne, U., Creighton, C. J., & Varambally, S. (2022). UALCAN: An update to the integrated cancer data analysis platform. Neoplasia, 25, 18–27. https://doi.org/10.1016/j.neo.2022.01.001
Chen, C., Tian, A., Zhou, H., Zhang, X., Liu, Z., & Ma, X. (2020). Upregulation of miR-211 Promotes Chondrosarcoma Development via Targeting Tumor Suppressor VHL. OncoTargets and Therapy, Volume 13, 2935–2943. https://doi.org/10.2147/OTT.S239887
Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T., & Lin, C.-Y. (2014). cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Systems Biology, 8(S4), 1–6. https://doi.org/10.1186/1752-0509-8-S4-S11
Chow, W. A. (2018). Chondrosarcoma: Biology, genetics, and epigenetics. F1000Research, 7, 1–7. https://doi.org/10.12688/f1000research.15953.1
Dai, X., Ma, W., He, X., & Jha, R. K. (2011). Review of therapeutic strategies for osteosarcoma,. Med Sci Monit, 177–190.
Dang, F., Nie, L., & Wei, W. (2021). Ubiquitin signaling in cell cycle control and tumorigenesis. Cell Death & Differentiation, 28(2), 427–438. https://doi.org/10.1038/s41418-020-00648-0
Debnath, J., Gammoh, N., & Ryan, K. M. (2023). Autophagy and autophagy-related pathways in cancer. Nature Reviews Molecular Cell Biology, 24(8), 560–575. https://doi.org/10.1038/s41580-023-00585-z
Farhan, M., Wang, H., Gaur, U., Little, P. J., Xu, J., & Zheng, W. (2017). FOXO Signaling Pathways as Therapeutic Targets in Cancer. International Journal of Biological Sciences, 13(7), 815–827. https://doi.org/10.7150/ijbs.20052
Fassl, A., Geng, Y., & Sicinski, P. (2022). CDK4 and CDK6 kinases: From basic science to cancer therapy. Science, 375(6577), 1–16. https://doi.org/10.1126/science.abc1495
Galoian, K., Guettouche, T., Issac, B., Navarro, L., & Temple, H. T. (2014). Lost miRNA surveillance of Notch, IGFR pathway—Road to sarcomagenesis. Tumor Biology, 35(1), 483–492. https://doi.org/10.1007/s13277-013-1068-5
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., & Schultz, N. (2013). Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling, 6(269), 1–18. https://doi.org/10.1126/scisignal.2004088
Gheghiani, L., Shang, S., & Fu, Z. (2020). Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer. Scientific Reports, 10(1), 1–10. https://doi.org/10.1038/s41598-020-69338-8
Guan, H., Tan, P., Xie, L., Mi, B., Fang, Z., Li, J., Yue, J., Liao, H., & Li, F. (2015). FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression. Oncogenesis, 4(9), 1–11. https://doi.org/10.1038/oncsis.2015.25
Han, G. H., Chay, D. B., Nam, S., Cho, H., Chung, J.-Y., & Kim, J.-H. (2019). Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer. BMC Cancer, 19(1), 1–9. https://doi.org/10.1186/s12885-019-6406-6
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hornsveld, M., Dansen, T. B., Derksen, P. W., & Burgering, B. M. T. (2018). Re-evaluating the role of FOXOs in cancer. Seminars in Cancer Biology, 50, 90–100. https://doi.org/10.1016/j.semcancer.2017.11.017
Hsu, J. Y., Seligson, N. D., Hays, J. L., Miles, W. O., & Chen, J. L. (2022). Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges. JCO Precision Oncology, 6, 1–9. https://doi.org/10.1200/PO.21.00211
Hua, K.-C., & Hu, Y.-C. (2020). Treatment method and prognostic factors of chondrosarcoma: Based on Surveillance, Epidemiology, and End Results (SEER) database. Translational Cancer Research, 9(7), 4250–4266. https://doi.org/10.21037/tcr-20-357
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1), 44–57. https://doi.org/10.1038/nprot.2008.211
Iorio, M. V., & Croce, C. M. (2009). MicroRNAs in Cancer: Small Molecules With a Huge Impact. Journal of Clinical Oncology, 27(34), 5848–5856. https://doi.org/10.1200/JCO.2009.24.0317
Iorio, M. V., & Croce, C. M. (2012). MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Molecular Medicine, 4(3), 143–159. https://doi.org/10.1002/emmm.201100209
Jami, S. A., Jiandang, S., Hao, L. C., Xi, Z., Wenqi, Y., & Zhou, Z. (2021). Comparison of chondrosarcoma cases: Current clinical situations among institutions. International Journal of Health Sciences, 15(4), 42–48.
Jiménez‐Santos, M. J., García‐Martín, S., Fustero‐Torre, C., Di Domenico, T., Gómez‐López, G., & Al‐Shahrour, F. (2022). Bioinformatics roadmap for therapy selection in cancer genomics. Molecular Oncology, 16(21), 3881–3908. https://doi.org/10.1002/1878-0261.13286
Jiramongkol, Y., & Lam, E. W.-F. (2020). FOXO transcription factor family in cancer and metastasis. Cancer and Metastasis Reviews, 39(3), 681–709. https://doi.org/10.1007/s10555-020-09883-w
Kanehisa, M., & Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. 28(1), 27–30.
Li, F., Xu, J., Zhu, Y., Sun, L., & Zhou, R. (2020). Analysis of Cells Proliferation and MicroRNAs Expression Profile in Human Chondrosarcoma SW1353 Cells Exposed to Iodine-125 Seeds Irradiation. Dose-Response, 18(2), 1–9. https://doi.org/10.1177/1559325820920525
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017). TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Research, 77(21), 108–110. https://doi.org/10.1158/0008-5472.CAN-17-0307
Li, Z., Zhu, Z., Wang, Y., Wang, Y., Li, W., Wang, Z., Zhou, X., & Bao, Y. (2021). Hsa‑miR‑15a‑5p inhibits colon cell carcinoma via targeting CCND1. Molecular Medicine Reports, 24(4), 1–7. https://doi.org/10.3892/mmr.2021.12375
Min, L., Choy, E., Pollock, R. E., Tu, C., Hornicek, F., & Duan, Z. (2017). Autophagy as a potential target for sarcoma treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1868(1), 40–50. https://doi.org/10.1016/j.bbcan.2017.02.004
Mulcahy Levy, J. M., & Thorburn, A. (2020). Autophagy in cancer: Moving from understanding mechanism to improving therapy responses in patients. Cell Death & Differentiation, 27(3), 843–857. https://doi.org/10.1038/s41418-019-0474-7
Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., Zehir, A., Gounder, M. M., Bowler, T. G., Luthra, A., Jadeja, B., Okada, A., Strong, J. A., Stoller, J., Chan, J. E., … Tap, W. D. (2022). Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 13(1), 1–13. https://doi.org/10.1038/s41467-022-30453-x
Nguyen, H.-M., Gaikwad, S., Oladejo, M., Agrawal, M. Y., Srivastava, S. K., & Wood, L. M. (2023). Interferon stimulated gene 15 (ISG15) in cancer: An update. Cancer Letters, 556, 1–10. https://doi.org/10.1016/j.canlet.2023.216080
Ni, Y., Yang, Y., Ran, J., Zhang, L., Yao, M., Liu, Z., & Zhang, L. (2020). MiR-15a-5p inhibits metastasis and lipid metabolism by suppressing histone acetylation in lung cancer. Free Radical Biology and Medicine, 161, 150–162. https://doi.org/10.1016/j.freeradbiomed.2020.10.009
Pansuriya, T. C., Van Eijk, R., d’Adamo, P., Van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., Van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., Van Wezel, T., Nord, K. H., Sangiorgi, L., Toker, B., Liegl-Atzwanger, B., San-Julian, M., Sciot, R., Limaye, N., Kindblom, L.-G., … Bovée, J. V. M. G. (2011). Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics, 43(12), 1256–1261. https://doi.org/10.1038/ng.1004
Patergnani, S., Missiroli, S., Morciano, G., Perrone, M., Mantovani, C. M., Anania, G., Fiorica, F., Pinton, P., & Giorgi, C. (2021). Understanding the Role of Autophagy in Cancer Formation and Progression Is a Real Opportunity to Treat and Cure Human Cancers. Cancers, 13(22), 1–25. https://doi.org/10.3390/cancers13225622
Polychronidou, G., Karavasilis, V., Pollack, S. M., Huang, P. H., Lee, A., & Jones, R. L. (2017). Novel therapeutic approaches in chondrosarcoma. Future Oncology, 13(7), 637–648. https://doi.org/10.2217/fon-2016-0226
Quan, X., Zhao, C., Gao, Z., Zhang, Y., Zhao, R., Wang, J., & Zhang, Q. (2021). DDX10 and BYSL as the potential targets of chondrosarcoma and glioma. Medicine, 100(46), 1–10. https://doi.org/10.1097/MD.0000000000027669
Reumann, S., Shogren, K. L., Yaszemski, M. J., & Maran, A. (2016). Inhibition of Autophagy Increases 2-Methoxyestradiol-Induced Cytotoxicity in SW1353 Chondrosarcoma Cells: I NHIBITION OF A UTOPHAGY I NCREASES 2-M ETHOXYESTRADIOL -I NDUCED C YTOTOXICITY. Journal of Cellular Biochemistry, 117(3), 751–759. https://doi.org/10.1002/jcb.25360
Scotlandi, K., Hattinger, C. M., Pellegrini, E., Gambarotti, M., & Serra, M. (2020). Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors. Cells, 9(4), 1–18. https://doi.org/10.3390/cells9040968
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016). Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discovery, 6(4), 353–367. https://doi.org/10.1158/2159-8290.CD-15-0894
Suyasa, I., Nugraha, G., & Eka Wiratnaya, I. (2019). Primary Malignant Bone Tumor Chondrosarcoma of The Sternum. Jurnal Medika Udayana, 8(10), 1–4.
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., Kuhn, M., Bork, P., Jensen, L. J., & von Mering, C. (2015). STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Research, 43(D1), 447–452. https://doi.org/10.1093/nar/gku1003
Tlemsani, C., Larousserie, F., De Percin, S., Audard, V., Hadjadj, D., Chen, J., Biau, D., Anract, P., Terris, B., Goldwasser, F., Pasmant, E., & Boudou-Rouquette, P. (2023). Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options. International Journal of Molecular Sciences, 24(2), 1–15. https://doi.org/10.3390/ijms24021361
Urdinez, J., Boro, A., Mazumdar, A., Arlt, M. J., Muff, R., Botter, S. M., Bode‐Lesniewska, B., Fuchs, B., Snedeker, J. G., & Gvozdenovic, A. (2020). The miR‐143/145 Cluster, a Novel Diagnostic Biomarker in Chondrosarcoma, Acts as a Tumor Suppressor and Directly Inhibits Fascin‐1. Journal of Bone and Mineral Research, 35(6), 1077–1091. https://doi.org/10.1002/jbmr.3976
Van Rooij, E., & Olson, E. N. (2012). MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nature Reviews Drug Discovery, 11(11), 860–872. https://doi.org/10.1038/nrd3864
Wu, T., Cao, H., Liu, L., & Peng, K. (2020). Identification of Key Genes and Pathways for Enchondromas by Bioinformatics Analysis. Dose-Response, 18(1), 1–8. https://doi.org/10.1177/1559325820907536
Xia, J., Benner, M. J., & Hancock, R. E. W. (2014). NetworkAnalyst—Integrative approaches for protein–protein interaction network analysis and visual exploration. Nucleic Acids Research, 42(1), 167–174. https://doi.org/10.1093/nar/gku443
Yuan, Y., Qin, H., Li, H., Shi, W., Bao, L., Xu, S., Yin, J., & Zheng, L. (2023). The Functional Roles of ISG15/ISGylation in Cancer. Molecules, 28(3), 1–12. https://doi.org/10.3390/molecules28031337
Zhou, M.-J., Chen, F.-Z., Chen, H.-C., Wan, X.-X., Zhou, X., Fang, Q., & Zhang, D.-Z. (2017). ISG15 inhibits cancer cell growth and promotes apoptosis. International Journal of Molecular Medicine, 39(2), 446–452. https://doi.org/10.3892/ijmm.2016.2845
Zhu, G. G., Nafa, K., Agaram, N., Zehir, A., Benayed, R., Sadowska, J., Borsu, L., Kelly, C., Tap, W. D., Fabbri, N., Athanasian, E., Boland, P. J., Healey, J. H., Berger, M. F., Ladanyi, M., & Hameed, M. (2020). Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 26(2), 419–427. https://doi.org/10.1158/1078-0432.CCR-18-4212
Zulfariska, N., Martadiani, E. D., Wiratnaya, I. G. E., Ambong, H. A., & Sumadi, I. W. J. (2020). Variasi kondrosarkoma pada usia muda: Serial kasus. Medicina, 51(3), 567–570. https://doi.org/10.15562/medicina.v51i3.842
Copyright (c) 2023 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
